Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 8/20 | 0.45 |
| ▸ | SYK | P43405 | 5/20 | 0.38 |
| ▸ | SRC | P12931 | 2/20 | 0.38 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.36 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.34 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.33 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1633882 | 0.88 | SYK (0.47) | SYKSRCZAP70JAK2JAK1 | |
| SCHEMBL1571587 | 0.83 | CYP1A2 (0.44) | SYKSRCZAP70JAK2JAK1 | |
| SCHEMBL1634643 | 0.82 | SYK (0.53) | SYKSRCZAP70JAK2JAK1 | |
| SCHEMBL13335980 | 0.79 | SYK (0.44) | SYKJAK2JAK1TYK2JAK3 | |
| SCHEMBL1632924 | 0.78 | PRKCZ (0.39) | SYKJAK2JAK1TYK2JAK3 | |
| SCHEMBL3465145 | 0.78 | PRKCQ (0.44) | PRKCQSYKSRCZAP70 | |
| SCHEMBL13336156 | 0.78 | BRAF (0.41) | SYKJAK2JAK1TYK2JAK3 | |
| SCHEMBL1633716 | 0.78 | PRKCZ (0.38) | SYKJAK2JAK1TYK2JAK3 | |
| SCHEMBL13336057 | 0.77 | BRAF (0.41) | SYKJAK2JAK1TYK2JAK3 | |
| SCHEMBL1571934 | 0.76 | JAK2 (0.42) | SYKJAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| EP-2004615-A2 | QUINAZOLINES FOR PDK1 INHIBITION | Novartis AG (CH) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007117607-A9 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2007117607-A9 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2007117607-A2 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007117607-A2 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | PRKCQ 150/4885SYK 4204/4885SRC 1131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.